1. Home
  2. PCRX vs ABCL Comparison

PCRX vs ABCL Comparison

Compare PCRX & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCRX
  • ABCL
  • Stock Information
  • Founded
  • PCRX 2006
  • ABCL 2012
  • Country
  • PCRX United States
  • ABCL Canada
  • Employees
  • PCRX N/A
  • ABCL N/A
  • Industry
  • PCRX Biotechnology: Pharmaceutical Preparations
  • ABCL Biotechnology: Pharmaceutical Preparations
  • Sector
  • PCRX Health Care
  • ABCL Health Care
  • Exchange
  • PCRX Nasdaq
  • ABCL Nasdaq
  • Market Cap
  • PCRX 1.2B
  • ABCL 1.1B
  • IPO Year
  • PCRX 2011
  • ABCL 2020
  • Fundamental
  • Price
  • PCRX $26.67
  • ABCL $4.18
  • Analyst Decision
  • PCRX Buy
  • ABCL Strong Buy
  • Analyst Count
  • PCRX 6
  • ABCL 5
  • Target Price
  • PCRX $30.00
  • ABCL $8.00
  • AVG Volume (30 Days)
  • PCRX 766.6K
  • ABCL 4.9M
  • Earning Date
  • PCRX 08-05-2025
  • ABCL 08-07-2025
  • Dividend Yield
  • PCRX N/A
  • ABCL N/A
  • EPS Growth
  • PCRX N/A
  • ABCL N/A
  • EPS
  • PCRX N/A
  • ABCL N/A
  • Revenue
  • PCRX $705,848,000.00
  • ABCL $32,875,999.00
  • Revenue This Year
  • PCRX $7.36
  • ABCL $15.60
  • Revenue Next Year
  • PCRX $10.07
  • ABCL $65.70
  • P/E Ratio
  • PCRX N/A
  • ABCL N/A
  • Revenue Growth
  • PCRX 2.25
  • ABCL N/A
  • 52 Week Low
  • PCRX $12.61
  • ABCL $1.89
  • 52 Week High
  • PCRX $27.64
  • ABCL $5.82
  • Technical
  • Relative Strength Index (RSI)
  • PCRX 67.86
  • ABCL 46.37
  • Support Level
  • PCRX $25.14
  • ABCL $4.20
  • Resistance Level
  • PCRX $27.04
  • ABCL $4.55
  • Average True Range (ATR)
  • PCRX 0.78
  • ABCL 0.29
  • MACD
  • PCRX 0.18
  • ABCL -0.04
  • Stochastic Oscillator
  • PCRX 88.79
  • ABCL 21.25

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Share on Social Networks: